Blockchain Registration Transaction Record

Soligenix CEO to Present at H.C. Wainwright Investment Conference Sept 2025

Soligenix CEO Christopher Schaber to present at H.C. Wainwright Investment Conference Sept 2025. Learn about their rare disease treatments and vaccine development programs.

This announcement matters because Soligenix represents a critical player in developing treatments for rare diseases and public health threats that often receive limited attention from larger pharmaceutical companies. Their work on cutaneous T-cell lymphoma, ricin toxin protection, and filovirus vaccines addresses significant unmet medical needs and national security concerns. For investors, the conference presentation offers valuable insight into a company positioned at the intersection of healthcare innovation and government-supported research, potentially representing both financial opportunity and contribution to important medical advancements that could benefit patients worldwide.